Press releases | WebDisclosure

Basculer en Français

9842	Companies
197720	Keywords
128809	Articles
105160	Press releases

Home
Press releases

PRESS RELEASE

published on 04/09/2025 at 07:30, 10 months 2 days ago

Bluelinea publie ses résultats annuels 2024 et son chiffre d'affaires du 1er trimestre 2025
Bluelinea présente ses résultats annuels 2024, sa trésorerie et son chiffre d'affaires du T1 2025. Malgré un contexte économique difficile, l'entreprise a amélioré ses performances

Chiffre D'affaires Croissance Résultats Annuels Trésorerie Bluelinea
PRESS RELEASE

published on 04/09/2025 at 07:30, 10 months 2 days ago

OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025
OSE Immunotherapeutics to present new data on Lusvertikimab's long-term benefits and safety in ulcerative colitis at DDW 2025, showcasing potential in autoimmune diseases

Ulcerative Colitis Immuno-oncology Inflammatory Diseases OSE Immunotherapeutics Lusvertikimab
PRESS RELEASE

published on 04/09/2025 at 07:30, 10 months 2 days ago

OSE Immunotherapeutics présentera des données inédites de la période d’extension de Lusvertikimab à la “Digestive Disease Week” (DDW) 2025
OSE Immunotherapeutics présentera des données inédites de la période d’extension de Lusvertikimab à la Digestive Disease Week (DDW) 2025

Rectocolite Hémorragique OSE Immunotherapeutics Lusvertikimab Anticorps Monoclonal Efficacité Et Sécurité
PRESS RELEASE

published on 04/09/2025 at 07:01, 10 months 2 days ago

Press release: Leonteq enters the market for listed leverage products in Switzerland
Leonteq announces the market launch of listed leverage products in Switzerland, listing over 2,500 products on SIX Swiss Exchange and planning expansion on BX Swiss

Switzerland Leonteq SIX Swiss Exchange Market Launch Listed Leverage Products
PRESS RELEASE

published on 04/09/2025 at 07:00, 10 months 2 days ago

ARYZTA issues AGM invitation
ARYZTA AG issues invitation to Annual General Meeting (AGM) scheduled for 09.04.2025. The international bakery company is based in Schlieren, Switzerland, with operations worldwide

SIX Swiss Exchange ARYZTA AG AGM Invitation Bakery Company Schlieren Switzerland
REGULATED PRESS RELEASE

published on 04/09/2025 at 07:00, 10 months 2 days ago

Biophytis confirme le lancement de l’essai clinique de Phase 2 OBA dans l’obésité
Biophytis confirme le lancement de l'essai clinique de Phase 2 OBA dans l'obésité en 2025, avec BIO101. Recherche d'un partenaire pharmaceutique pour le développement et le lancement du produit aux États-Unis

Biophytis Essai Clinique BIO101 Obésité Partenaire Pharmaceutique
REGULATED PRESS RELEASE

published on 04/09/2025 at 07:00, 10 months 2 days ago

Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
Biophytis confirms the Phase 2 OBA Clinical Trial launch in obesity, continuing development of BIO101 to reduce muscle strength loss. Seeking pharmaceutical partner for co-development

Biophytis BIO101 Obesity Pharmaceutical Partner Phase 2 OBA Clinical Trial
PRESS RELEASE

published on 04/09/2025 at 07:00, 10 months 2 days ago

Valneva et LimmaTech annoncent la vaccination du premier participant à l’étude pédiatrique de Phase 2 du candidat vaccin tétravalent contre la shigellose S4V2
Valneva et LimmaTech annoncent la vaccination du premier participant à l’étude pédiatrique de Phase 2 du candidat vaccin tétravalent contre la shigellose S4V2

Valneva Vaccin Shigellose LimmaTech Étude Pédiatrique
PRESS RELEASE

published on 04/09/2025 at 07:00, 10 months 2 days ago

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
Valneva and LimmaTech announce first vaccination in Phase 2 infant study of tetravalent Shigella vaccine candidate S4V2. Study aims to combat shigellosis, a deadly diarrheal disease

Valneva Phase 2 Study Shigella Vaccine Shigellosis LimmaTech
PRESS RELEASE

published on 04/09/2025 at 06:59, 10 months 2 days ago

Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
Biophytis confirms the launch of the Phase 2 OBA Clinical Trial in Obesity in 2025. The study aims to evaluate the efficacy of BIO101 in reducing muscle strength loss caused by GLP-1 agonists in obese patients

Biophytis BIO101 Obesity Muscle Strength Phase 2 OBA Clinical Trial

Accesswire

Published on 02/11/2026 at 14:35, 3 hours 55 minutes ago

Worksport Delivers Breakout Q4: Revenue Up 65% YoY, Gross Profit Up 380%
Published on 02/11/2026 at 14:30, 4 hours ago

Sekur Private Data CEO Updates on Growth, Market Expansion, Corporate Developments and New Product Launch
Published on 02/11/2026 at 14:00, 4 hours 30 minutes ago

Organto Foods Inc. Expands Scalable and Flexible Logistics Platform to Support 2026 Growth
Published on 02/11/2026 at 14:00, 4 hours 30 minutes ago

PPX Mining Provides Operational and Corporate Update
Published on 02/11/2026 at 14:00, 4 hours 30 minutes ago

Meta Critical Minerals Engages Quad Consulting Group to Advance Table Mountain Silica Project Development Strategy

View all ACCESSWIRE

EQS Group

Published on 02/11/2026 at 18:00, 30 minutes ago

Private Equity Holding AG: Net Asset Value as of January 31, 2026
Published on 02/11/2026 at 17:55, 34 minutes ago

POS-Transaction in Own Shares
Published on 02/11/2026 at 17:45, 45 minutes ago

Linedata Services: 2025 Annual Results - Revenue: €169.6 m (-7.7%) EBITDA margin: 22.1% of revenue
Published on 02/11/2026 at 17:45, 45 minutes ago

Linedata Services: Résultats annuels 2025 - Chiffre d’affaires : 169,6 M€ (-7,7%) Marge d’EBITDA : 22,1% du CA
Published on 02/11/2026 at 17:00, 1 hour 30 minutes ago

Mutares has completed the acquisition of Venator Ultramarine Blue Pigments business from Venator France SAS

Les Echos

Published on 02/11/2026 at 17:45, 45 minutes ago

Infotel : Stake held in AeroEx. A publisher of digital compliance and safety solutions for the aerospace industry.
Published on 02/11/2026 at 17:45, 45 minutes ago

Infotel : Prise de participation dans AeroEx éditeur de solutions digitales de conformité et de sécurité pour l’industrie aéronautique.
Published on 02/11/2026 at 11:25, 7 hours 4 minutes ago

Innelec : Mise à disposition du rapport financier semestriel 2025-26
Published on 02/11/2026 at 08:00, 10 hours 30 minutes ago

Imerys-press-release French State acquisition stake Emili Lithium
Published on 02/11/2026 at 08:00, 10 hours 30 minutes ago

Imerys-communique-de-presse prise participation Etat Français Projet lithium Emili

View all LES ECHOS COMFI WIRE